Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy - Tập 66 Số 5 - 2022
Marco Falcone1, Giusy Tiseo1, Alessandro Leonildi2, Leonardo Della Sala1, Alessandra Vecchione2, Simona Barnini2, Alessio Farcomeni3, Francesco Forfori1
1Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
2Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
3Department of Economics and Finance, University of Rome Tor Vergata, Rome, Italy

Tóm tắt

Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, but clinical data are limited. This is an observational retrospective study conducted in the University Hospital of Pisa including consecutive patients with CRAB infections (January 2020 to August 2021).

Từ khóa


Tài liệu tham khảo

World Health Organization. 2021. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

10.1016/S1473-3099(18)30099-9

10.1017/S095026881200194X

10.1093/jac/dkaa530

10.1007/s15010-021-01643-4

10.1038/srep17091

10.1016/j.ijantimicag.2011.10.001

10.1093/jac/dkx368

US Food and Drug Administration. 2019. Highlights of prescribing information: Fetroja (Cefiderocol). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209445s000lbl.pdf.

10.1016/S1473-3099(20)30796-9

10.1093/cid/ciaa1410

10.3390/antibiotics10060652

10.1128/AAC.02435-13

10.1093/jac/dkz123

10.1093/jac/dkab280

10.1038/s41564-019-0480-z

10.1016/S1473-3099(21)00194-8

10.1016/j.cmi.2018.03.037

10.1128/AAC.00831-15

10.1128/AAC.00877-21

10.1128/AAC.01221-20

10.1016/j.sapharm.2005.12.001

10.1016/j.ijantimicag.2013.01.020

10.1093/cid/cis270

10.1186/s12941-017-0199-8

10.1007/s15010-021-01663-0

10.1186/s13054-020-03013-2

10.1111/1469-0691.12716

CDC. 2021. CDC/NHSN Surveillance Definitions for Specific Types of Infections. https://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf.

10.1016/j.cmi.2021.06.031

KDIGO. 2012. KDIGO clinical practice guideline for acute kidney injury. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf.

10.1186/s13054-020-2742-9

The European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters Version 11.0. http://www.eucast.org.

CLSI. 2021. Performance standards for antimicrobial susceptibility testing. M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.

FDA. 2021. FDA susceptibility test interpretive criteria. https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria.

10.1093/cid/ciaa586

10.1371/journal.pone.0018174

10.1002/sim.6607

Thông tin
Thông tin xuất bản

Antimicrobial Agents and Chemotherapy

Tập 66 Số 5

Thông tin tác giả